Analyzing Regulation and Development

Regulation and Development In general, should the FDA adopt a liberal (increased risk) or conservative (increased safety) approach to approving medical products and why? In accordance to Eichler et al. (2013), drugs are sanctioned by supervisory organizations on the basis of their evaluation of whether the accessible evidence designates that the benefits of the drug prevail over its risks. In general, the United States Food and Drug Administration (FDA) ought to adopt a liberal or increased risk approach to approving medical products.

This is for the reason that in the recent number of years, regulatory agencies have been censured and condemned both for being exceptionally risk-averse, which mirrors the problem in determining a suitable poise between benefit and risk with the restricted data that is usually accessible prior to drug approval (Eichler et al., 2013). The regulation of drugs in the United States in contemporary years has in actual fact come to be more and more risk-averse.

This is owing to the fact that the FDA has gradually raised the bar for the instigation and development of clinical testing of new drugs. This has caused the agency to turn out to be even more conservative and wary in its decision-making (Miller and Henderson, 2007). A good example as pointed out by Miller and Henderson (2007) encompasses the drug approval of Avastin, which is a colon cancer drug for the cure of breast cancer.

This was owing to the fact that the drug was postponed for a minimum of a year due to demands from the FDA for extra data and information. Taking this into account, it is suggested for the agency to be best in alignment with accepting risk and becoming more liberal for the interests of public health (Eichler et al., 2013).

What effect will the regulatory approach you endorse have on the development, manufacturing, and marketing of these products? The regulatory approach taken will have a positive and constructive effect on the development, manufacturing, and marketing of these products. This is in the sense that it removes the obstacles that hinder these business functions in developing the product. This implies that the development and manufacturing of the product will be undertaken in a faster process and have better marketing, devoid of any goalposts (Miller and Henderson, 2007).

How well have the incentives provided by the Orphan Drug Act worked? Are they justified and adequate for addressing rare disorders? To start with, prior to the enactment of the Orphan Drug Act (ODA), drug developers were frequently tentative and cautious to place investment in developing new treatments for rare diseases, owing to the small patient populaces that made it problematic to recuperate development expenses. The incentives provided by the Orphan Drug Act (ODA) have worked effectively.

This is taking into consideration the fact that subsequent to the enactment of the law, there has been the approval of 486 orphan products. This encompasses a combination of more successful formulations, new signs, prescribed amounts, and sources of drug supply. In this period, there has been the approval of over 200 new orphan drugs by the FDA (Ernst and Young, 2015). These, in fact, are justified and adequate for addressing rare disorders. This particular Act permits orphan drug developers to obtain a tax credit for 50%.